Clinical and Histopathological Characteristics of HER2 Low-Expressing Breast Cancer

被引：0
|
作者：
Lee, Soo Hyun [1 ]
Young, Kristen [2 ]
Sofoluwe, Adeyemi [2 ]
Jacoba, Isa [1 ]
Narasimhan, Ramya [2 ]
Zhao, Qing [1 ]
Zuo, Tao [3 ]
机构：
[1] Boston Univ, Sch Med, Boston Med Ctr, Boston, MA 02118 USA
[2] Boston Med Ctr, Boston, MA USA
[3] Boston Univ, Mallory Pathol Associates, Boston, MA 02215 USA
来源：
LABORATORY INVESTIGATION | 2023年 / 103卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
174
引用
收藏
页码：S162 / S163
页数：2
相关论文
共 50 条
  • [31] Radiolabelled Trastuzumab Fab as a theranostic agent for HER2 expressing breast cancer
    Shukla, Jaya
    Rathore, Yogesh
    Kaur, Komalpreet
    Irrinky, Santosh
    Kumar, Rajender
    Bal, Amanjit
    Mittal, Bhagwant R.
    CANCER RESEARCH, 2024, 84 (03)
  • [32] THE ROLE OF ADAM17 IN HER2 MODERATELY EXPRESSING BREAST CANCER
    Feldinger, K.
    Kerry, J.
    Gijsen, M.
    Murphy, G.
    Kong, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 39 - 39
  • [33] HER2 Intratumoral Heterogeneity in Breast Cancer: Clinicopathologic Characteristics
    Muller, Kristen E.
    Marotti, Jonathan
    Tafe, Laura
    MODERN PATHOLOGY, 2018, 31 : 93 - 93
  • [34] HER2 Intratumoral Heterogeneity in Breast Cancer: Clinicopathologic Characteristics
    Muller, Kristen E.
    Marotti, Jonathan
    Tafe, Laura
    LABORATORY INVESTIGATION, 2018, 98 : 93 - 93
  • [35] Prognostic significance and evolution of HER2 zero, HER2 low and HER2 positive in breast cancer after neoadjuvant treatment
    Wei, T.
    Wang, D.
    Peng, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S301 - S302
  • [36] Her2 low status and response to neoadjuvant chemotherapy in Her2 negative early breast cancer
    Mattos, Bruna RaphaeliSilva
    Cesca, Marcelle Goldner
    Leite, Luciana de Moura
    Tavares, Monique Celeste
    Silva, Sinara Figueiredo
    Pirolli, Rafaela
    Fogassa, Camilla AlbinaZanco
    Silva, Erick Figueiredo
    Rocha, Francisca Giselle
    Loose, Simone Klug
    Campos, Fernando AugustoBatista
    Sanches, Solange Moraes
    de Lima, Vladmir ClaudioCordeiro
    Ponde, Noam Falbel
    CANCER RESEARCH, 2021, 81 (04)
  • [37] The comparison of HER2 low and HER2 0 in ductal carcinoma in situ (DCIS) for breast cancer
    Kureyama, Nari
    Kusudo, Maho
    Nakakami, Akira
    Komaki, Rie
    Endo, Yuka
    Nozawa, Kazuki
    Kataoka, Ayumi
    Kotani, Haruru
    Yoshimura, Akiyo
    Hattori, Masaya
    Sawaki, Masataka
    Iwata, Hiroji
    CANCER RESEARCH, 2024, 84 (09)
  • [38] HER2 shedding and serum HER2 extracellular domain: Biology and clinical utility in breast cancer
    Tse, Chantal
    Gauchez, Anne-Sophie
    Jacot, William
    Lamy, Pierre-Jean
    CANCER TREATMENT REVIEWS, 2012, 38 (02) : 133 - 142
  • [39] HER2-Low Breast Cancer Can Be Visualized by HER2 PET
    Altena, Renske
    af Buren, Siri
    Tran, Thuy
    Axelsson, Rimma
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (11) : 1842 - 1842
  • [40] Improving HER2 testing reproducibility in HER2-low breast cancer
    Sajjadi, Elham
    Venetis, Konstantinos
    Ivanova, Mariia
    Fusco, Nicola
    CANCER DRUG RESISTANCE, 2022, 5 (04) : 882 - 888
12345